NCT04439201 2026-03-18
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
31 trialsNCT04439292 2026-03-18
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439318 2026-03-18
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439331 2026-03-18
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439357 2026-03-18
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06303167 2026-03-18
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04557098 2026-03-12
MajesTEC-1
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT02210078 2026-02-17
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02861417 2026-02-17
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01949662 2026-02-13
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01628029 2026-02-04
Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04395222 2026-01-06
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT05256537 2025-12-08
OmitMMF
Cedars-Sinai Medical Center
Phase 2 Active not recruiting
NCT04439110 2025-11-21
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439149 2025-11-21
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439188 2025-11-19
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439266 2025-11-19
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439279 2025-11-19
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439344 2025-11-19
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439175 2025-11-18
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04060277 2025-11-14
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04439227 2025-10-31
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05246670 2025-09-22
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT04439253 2025-09-18
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01810588 2025-09-02
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT03399773 2025-08-26
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT01594723 2025-07-23
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Eli Lilly and Company
Phase 2 Active not recruiting
NCT04552288 2025-07-23
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03413800 2024-08-21
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
Ciusss de L'Est de l'Île de Montréal
Phase 2 Active not recruiting
NCT05493800 2024-05-29
Capella
MitoImmune Therapeutics
Phase 2 Active not recruiting
NCT01428973 2024-05-09
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
University of Liege
Phase 2 Active not recruiting